Mylan (MYL) – Research Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Mylan (NASDAQ: MYL) recently:

  • 2/3/2018 – Mylan was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 1/26/2018 – Mylan was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 1/25/2018 – Mylan had its “positive” rating reaffirmed by analysts at Susquehanna Bancshares Inc. They now have a $55.00 price target on the stock, up previously from $47.00.
  • 1/24/2018 – Mylan was given a new $50.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 1/18/2018 – Mylan was given a new $43.00 price target on by analysts at Wells Fargo & Co. They now have a “hold” rating on the stock.
  • 1/17/2018 – Mylan was upgraded by analysts at TheStreet from a “c” rating to a “b-” rating.
  • 1/16/2018 – Mylan was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Mylan received a major boost with the FDA approval for a generic version of Copaxone 40mg. The company being one of the first filers, will also enjoy 180 days of exclusivity. The FDA approval of biosimilar version of Herceptin will also boost the biosimilars portfolio. However, Mylan’s performance in 2017 was impacted by ongoing challenges in North America. The third quarter experienced an accelerated decline in EpiPen sales due to the launch of an authorized generic as well as the contraction of the overall epinephrine auto-injector market. Sales are expected to decline further. Moreover, the complete response letter from the FDA regarding its abbreviated new drug application ANDA for the generic version of asthma drug Advair Diskus was a setback given the market potential. Shares have performed better than the industry in the last one year.”
  • 1/11/2018 – Mylan had its price target raised by analysts at Goldman Sachs Group Inc from $46.00 to $52.00. They now have a “buy” rating on the stock.
  • 1/9/2018 – Mylan was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Mylan’s performance in 2017 was impacted by ongoing challenges in North America. The third quarter experienced an accelerated decline in EpiPen sales due to the launch of an authorized generic as well as the contraction of the overall epinephrine auto-injector market. Sales are expected to decline further. In a major boost, Mylan received FDA approval for a generic version of Copaxone 40mg. The company being one of the first filers, will also enjoy 180 days of exclusivity. The FDA approval of biosimilar version of Herceptin will also boost the biosimilars portfolio. However, the complete response letter from the FDA regarding its abbreviated new drug application ANDA for the generic version of asthma drug Advair Diskus was a setback given the market potential. Shares have performed better than the industry in the last six months.”
  • 1/4/2018 – Mylan had its “buy” rating reaffirmed by analysts at Citigroup Inc. They now have a $58.00 price target on the stock, up previously from $48.00.
  • 1/2/2018 – Mylan is now covered by analysts at Leerink Swann. They set a “market perform” rating and a $44.00 price target on the stock.
  • 12/26/2017 – Mylan was given a new $41.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 12/19/2017 – Mylan was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.

Shares of Mylan (NASDAQ:MYL) traded up $1.32 on Monday, hitting $40.60. The stock had a trading volume of 7,888,538 shares, compared to its average volume of 6,246,290. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. The stock has a market cap of $21,070.00, a PE ratio of 24.46, a PEG ratio of 1.06 and a beta of 1.35. Mylan has a fifty-two week low of $29.39 and a fifty-two week high of $47.82.

In other news, CEO Heather M. Bresch sold 75,000 shares of Mylan stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total value of $3,375,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.69% of the company’s stock.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply